Balanced news tone
News Sentiment
MSB sentiment intelligence
Mesoblast Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
93/100 classification confidence.
directly relevant articles
high-authority source matches
+8.7% over one week, +14.9% over four weeks, trend inactive, and materially above fair value.
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 02:06
- Source
- Kalkine
Mesoblast (ASX: MSB) Leaps 4.83% To AUD 2.72 As Biotech Buyers Return
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 10:09
- Source
- Kalkine
Mesoblast (ASX:MSB) shares Jump :Is the Market Betting Big on Ryoncil's Next Chapter?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 07:25
- Source
- Kalkine
Mesoblast Limited (MESO) sees 278,571 director options lapse in July
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 10:06
- Source
- Stock Titan
Why Is Mesoblast (ASX:MSB) Leading the Next Wave of ASX Mid-Cap Healthcare?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 05:39
- Source
- Kalkine Media
Mesoblast (ASX:MSB) Climbs as Global Biotech Dealmaking Heats Up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 12:24
- Source
- Kalkine Media
Mesoblast Issues 2.25 Million Ordinary Shares Under Employee Share Option Plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 09:54
- Source
- Kalkine
Mesoblast (ASX:MSB) Shares Rise: A Closer Look at the Cell Therapy Company's Market Position
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 07:27
- Source
- Kalkine
Mesoblast (ASX:MSB) Shares Surge: Why This ASX Biotechnology Stock Is Back in Focus
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jul 2026 07:13
- Source
- Kalkine
Why Mesoblast shares could double in value
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 21:17
- Source
- The Motley Fool Australia
Mesoblast (ASX:MSB) Posts Record Quarterly Revenue
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 10 Jul 2026 02:21
- Source
- Kalkine
Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- simplywall.st
Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Kalkine
Mesoblast (ASX:MSB) Why This Biotech Refuses To Leave Spotlight
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Kalkine
What Is Driving Increased Trading Activity in Mesoblast (ASX:MSB) Stock?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Kalkine
Mesoblast (ASX:MSB) Leads ASX Gainers Following High-Volume Trading Session
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Kalkine
Mesoblast Advances CAR Cell Therapy Platform And Late Stage Pain Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- simplywall.st
Why are Mesoblast shares jumping 8% today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- The Motley Fool Australia
Mesoblast Limited: A Risk/Reward Story (NASDAQ:MESO)
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- Seeking Alpha
Mesoblast says Ryoncil is nearing $100M as new trials move ahead
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Apr 2026 07:00
- Source
- Stock Titan
Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Apr 2026 07:00
- Source
- Market source
Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 08 Apr 2026 07:00
- Source
- simplywall.st
Mesoblast to spotlight multi-billion pipeline at April 8 R&D Day
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- Stock Titan
Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 08:00
- Source
- simplywall.st
Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance – Has The Bull Case Changed?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Feb 2026 08:00
- Source
- Market source
Mesoblast (ASX:MSB): Reassessing Valuation After Recent Share Price Rebound and Long-Term Return Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Dec 2025 08:00
- Source
- Market source
Mesoblast Limited (ASX:MSB): Are Analysts Optimistic?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Nov 2025 08:00
- Source
- Market source
Mesoblast (ASX:MSB): Assessing Valuation Following Recent Share Price Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Oct 2025 07:00
- Source
- Market source